Trial Profile

Early Treatment of Heart Failure: a Non-interventional Observational Study Program of Patients With Heart Failure and Initiated on Dapagliflozin (EVOLUTION-HF - UK)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapagliflozin (Primary)
Indications Heart failure
Focus Therapeutic Use
Acronyms EVOLUTION-HF
Sponsors AstraZeneca

Most Recent Events

24 Apr 2024 Status changed from active, no longer recruiting to completed.
28 Aug 2023 Results of a real-world analysis assessing utilization of heart failure medicines in England using data from this trial presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
18 Aug 2023 Planned End Date changed from 1 Mar 2024 to 2 Mar 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com